This discrepancy may be due to the use of different IHC assessment strategies, limited follow-up data as well as the larger proportion of advanced tumours in the latter study, as the prognostic value of RBM3 was found to be more evident in non-muscle-invasive tumours [13, 14]. This evidence concerns the gene RBM3 and neoplasm.